-

Paragonix Technologies Raises $24M in Series B Led by Signet Healthcare Partners

Leader in organ transplant technologies secures institutional growth capital to drive organ preservation innovation and commercial expansion

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies’ commercial footprint, including its ongoing extension of clinical service offerings and inventory expansion, and will enable the Company to further advance transplant innovations.

Paragonix Technologies, a leading developer and manufacturer in the organ transplant industry, offers three FDA-cleared and CE-marked devices: Paragonix SherpaPak®, LUNGguard Donor Lung Preservation System, and the LIVERguard System. All three devices utilize first-of-its-kind preservation methods that present a significant improvement over traditional ice and cooler practices still used today. Paragonix devices combine clinically-proven, stable preservation technology with a comprehensive clinical support network, augmented by the largest clinical registries of organ preservation data worldwide. They also incorporate digital tracking and communication technologies to provide complete control over organ tracking, monitoring, and reporting.

“The future of Paragonix is full of promise and excitement. Our focus remains on creating the best possible product to help more people receive a second chance at life in a safe and effective manner,” said Dr. Lisa Anderson, CEO of Paragonix Technologies. “This growth investment arrives at a critical moment as we strive to meet rising demands for our organ preservation products. We are excited to rapidly advance our innovation pipeline to enhance our ability to safely preserve and transport as many donor organs as possible. We are thrilled to have Signet as our partner in accelerating growth and achieving our ambitious long-term strategic objectives, and we look forward to leveraging their vast experience in the medical device market.”

Ashley Friedman, Managing Director at Signet Healthcare Partners, stated, "At Signet, we seek to invest in highly innovative and fast-growing healthcare companies. Paragonix has rapidly become a leader in the organ transplant market and is having a significant impact on the future of transplant medicine. We are impressed by their commercial and clinical achievements to date and are excited to partner with their dedicated and versatile team during the next phase of growth."

In 2022, over 1 in 5 thoracic donor organs transplanted in the U.S. were preserved and transported using a Paragonix device. The Paragonix SherpaPak® System is the most commonly utilized FDA-cleared and CE-marked medical device for U.S. heart preservation and transport. According to 2022 transplant data, 19 out of the 30 largest U.S. heart transplant programs, as well as over 80 global transplant programs, rely on Paragonix devices to safely preserve, track, and transport critical donor organs to their intended recipients.

Gunderson Dettmer acted as legal counsel for Paragonix Technologies. Sheppard, Mullin, Richter & Hampton LLP and Knobbe Martens acted as legal counsel for Signet Healthcare Partners. Terms of the transaction were not disclosed.

About Paragonix Technologies

Paragonix Technologies (“Paragonix”) is a leading provider of Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ in transit. Every Paragonix AOP device natively integrates with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonixtechnologies.com

About Signet Healthcare Partners

Signet Healthcare Partners ("Signet") is a leading provider of growth capital to innovative healthcare companies, specializing in pharmaceutical and medical device sectors. The firm maintains a disciplined, yet flexible investment approach and collaborates closely with its portfolio companies to enhance value. With a proven track record of successful investments over its 25-year history, Signet has raised cumulative capital commitments exceeding $500 million and invested in over 55 companies. For more information, visit www.signethealthcarepartners.com

Follow us on Twitter: @ParagonixSherpa
Connect with us on LinkedIn: Paragonix Technologies
Like Us on Facebook: Paragonix SherpaPak

Contacts

Media: Adam Lafreniere, Sr. Director, Marketing
marketing@paragonixtechnologies.com
L-420, Rev 0

Paragonix Technologies, Inc.


Release Versions

Contacts

Media: Adam Lafreniere, Sr. Director, Marketing
marketing@paragonixtechnologies.com
L-420, Rev 0

More News From Paragonix Technologies, Inc.

New Study Reports Reduction in Rehospitalization After Lung Transplantation Utilizing Paragonix Preservation Devices

WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announced new lung preservation research at the 45th ISHLT Annual Meeting and Scientific Sessions. Drawing on data from the GUARDIAN-Lung Registry, the first and largest global clinical registry for studying lung preservation, investigators presented the largest analysis of the registry to date, demonstrating that Paragonix hypothermic preservation significantly red...

New Study Reports Increased 4-Year Survival in Heart Transplant Patients when Utilizing the Paragonix SherpaPak System

WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a leader in organ transplant technologies and organ procurement services, announces new research presented during the 45th ISHLT Annual Meeting and Scientific Sessions. The expansive study compared long-term outcomes of donor hearts preserved with the Paragonix SherpaPak® Cardiac Transport System, an FDA-cleared and CE-marked device, to those stored on conventional ice storage over four years post transplantation. Drawing on data from the...

Paragonix Launches Initiative to Increase Donor Lung Utilization

WALTHAM, Mass.--(BUSINESS WIRE)--Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, today announced the launch of its OPO Expanded Lung Utilization Initiative - designed to increase lung utilization by providing Organ Procurement Organizations (OPOs) with access to its advanced BAROguard™ preservation device to enable rapid procurement of extended criteria donor lungs. Indiana Donor Network, based in Indianapolis, is among the first to participate...
Back to Newsroom